Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Difimicin

Known as: diffimicin 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Tiacumicin B (1, also known as fidaxomicin or difimicin) is a marketed drug for the treatment of Clostridium difficile infections… Expand
Review
2015
Review
2015
Oral vancomycin and oral metronidazole have several limitations with regard to their use in the treatment of Clostridium… Expand
  • figure 1
  • table 2
Review
2014
Review
2014
OBJECTIVE To review the chemistry, pharmacology, microbiology, pharmacodynamics, pharmacokinetics, clinical efficacy… Expand
Review
2012
Review
2012
BACKGROUND Fidaxomicin, a macrolide antibiotic, was the first medication for the management of Clostridium difficile infections… Expand
Review
2012
Review
2012
The two drugs currently recommended for the treatment of Clostridium difficile infection (CDI), namely vancomycin and… Expand
  • figure 1
  • table 1
Review
2010
Review
2010
  • Drugs in R&D
  • 2010
  • Corpus ID: 195684967
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum… Expand
Review
2010
Review
2010
Objective: To evaluate the efficacy and safety of fidaxomicin for the treatment of Clostridium difficile infection. Data Sources… Expand
  • figure 1
  • table 1
  • table 2
Review
2009
Review
2009
  • J. Bartlett
  • Current infectious disease reports
  • 2009
  • Corpus ID: 33400777
Current drug treatment of Clostridium difficile infection (CDI) focuses on metronidazole and vancomycin. Early studies showed… Expand
Review
2008
Review
2008
Recent outbreaks of Clostridium difficile infection (CDI) in North America have been due to a more virulent, possibly more… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2